{"id":59,"date":"2011-10-19T14:41:21","date_gmt":"2011-10-19T18:41:21","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/ipcp\/?page_id=59"},"modified":"2021-02-22T13:06:46","modified_gmt":"2021-02-22T18:06:46","slug":"publications","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/ipcp\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

Publication of Clinical Trial Results<\/strong><\/p>\n

Politch JA, Cu-Uvin S, Moench TR, Tashima KT, Marathe JG, Guthrie KM, Cabral H, Nyhuis T, Brennan M, Zeitlin L, Spiegel HML, Mayer KH, Whaley KJ, Anderson DJ. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): \u00a0A Phase I randomized trial. PLoS Med, 2021;18(2):e1003495.<\/a><\/p>\n

__________________________________________________<\/p>\n

IPCP Investigators:<\/strong><\/p>\n

Journal of Infectious Diseases Supplement:\u00a0 Cell-Associated HIV Transmission Across Mucosal Surfaces:<\/a><\/p>\n

1.\u00a0 \u00a0 \u00a0 \u00a0\u00a0 Anderson DJ,<\/strong> Le Grand R. Cell-associated HIV mucosal transmission: the neglected pathway.<\/a>\u00a0 J Infect Dis<\/span>. 2014 Dec 15;210 Suppl 3:S606-8. doi: 10.1093\/infdis\/jiu538.<\/p>\n

2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Politch JA, Marathe J, Anderson DJ.<\/strong> Characteristics and quantities of HIV host cells in human genital tract secretions<\/a>.\u00a0 J Infect Dis<\/span>. 2014 Dec 15;210 Suppl 3:S609-15. doi: 10.1093\/infdis\/jiu390. Review.<\/p>\n

3. \u00a0 \u00a0 \u00a0 \u00a0\u00a0Cone RA.<\/strong> Vaginal microbiota and sexually transmitted infections that may influence transmission of cell-associated HIV<\/a>.\u00a0 J Infect Dis<\/span>. 2014 Dec 15;210 Suppl 3:S616-21. doi: 10.1093\/infdis\/jiu459. Review.<\/p>\n

4. \u00a0 \u00a0 \u00a0 \u00a0\u00a0Gummuluru S<\/strong>, Pina Ramirez NG, Akiyama H.\u00a0 CD169-dependent cell-associated HIV-1 transmission: a driver of virus dissemination.<\/a>\u00a0 J Infect Dis<\/span>. 2014 Dec 15;210 Suppl 3:S641-7. doi: 10.1093\/infdis\/jiu442. Review.<\/p>\n

5. \u00a0 \u00a0 \u00a0 \u00a0\u00a0Anderson DJ.<\/strong>\u00a0 Modeling mucosal cell-associated HIV type 1 transmission in vitro.<\/a>\u00a0 J Infect Dis<\/span>. 2014 Dec 15;210 Suppl 3:S648-53. doi: 10.1093\/infdis\/jiu537. Review.<\/p>\n

6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Moench TR.\u00a0<\/strong> Cell-associated transmission of HIV type 1 and other lentiviruses in small-animal models.<\/a>\u00a0 J Infect Dis<\/span>. 2014 Dec 15;210 Suppl 3:S654-9. doi: 10.1093\/infdis\/jiu368. Review.<\/p>\n

7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sagar M.\u00a0<\/strong> Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus.\u00a0<\/a> J Infect Dis<\/span>. 2014 Dec 15;210 Suppl 3:S667-73. doi: 10.1093\/infdis\/jiu369. Review.<\/p>\n

8. \u00a0 \u00a0 \u00a0\u00a0\u00a0 Whaley KJ, Mayer KH.<\/strong>\u00a0 Strategies for preventing mucosal cell-associated HIV transmission.\u00a0<\/a> J Infect Dis<\/span>. 2014 Dec 15;210 Suppl 3:S674-80. doi: 10.1093\/infdis\/jiu398. Review.<\/p>\n

Original and Review Articles:<\/span><\/p>\n

1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Daggett GJ Jr, Zhao C<\/strong>, Connor-Stroud F, Oviedo-Moreno P, Moon H, Cho MW, Moench T, Anderson DJ, Villinger F.<\/strong> Comparison of the vaginal environment in rhesus and cynomolgus macaques pre- and post-lactobacillus colonization.<\/a>\u00a0 J Med Primatol<\/em>. 2017 May 9. doi: 10.1111\/jmp.12264. [Epub ahead of print]<\/p>\n

2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zhao C,<\/strong> Gunawardana M, Villinger F,<\/strong> Baum MM, Remedios-Chan M, Moench TR, Zeitlin L, Whaley KJ,<\/strong> Bohorov O, Smith TJ, Anderson DJ. Moss JA.<\/strong> Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model.<\/a>\u00a0 Antimicrob Agents Chemother. <\/em><\/span>2017 Jun 27;61(7). pii: e02465-16. doi: 10.1128\/AAC.02465-16. Print 2017 Jul.<\/p>\n

3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>Anderson DJ, Politch JA, Zeitlin L, Hiatt A, Kadasia K, Mayer KH,<\/strong> Ruprecht RM, Villinger F, Whaley KJ<\/strong>.\u00a0 Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.<\/a>\u00a0 AIDS<\/em>. 2017 Jul 17;31(11):1505-1517. doi: 10.1097\/QAD.0000000000001521.<\/p>\n

4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Guthrie KM<\/strong>, Rohan L, Rosen RK, Vargas SE, Shaw JG, Katz D, Kojic EM, Ham AS, Friend D, Buckheit KW, Buckheit RW Jr.\u00a0 Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.<\/a>\u00a0 Pharm Dev Technol<\/em>. 2017 Jun 21:1-4. doi: 10.1080\/10837450.2017.1339085. [Epub ahead of print]<\/p>\n

5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Henry CE, Wang YY, Yang Q, Hoang T, Chattopadhyay S, Hoen T, Ensign LM, Nunn KL, Schroeder H, McCallen J, Moench T, Cone R,<\/strong> Roffler SR, Lai SK.<\/strong> Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.<\/a> Acta Biomater<\/em>.<\/a> 2016 Oct 1;43:61-70. doi: 10.1016\/j.actbio.2016.07.019. Epub 2016 Jul 14.<\/p>\n

6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ayehunie S, Islam A,<\/strong> Cannon C, Landry T, Pudney J,<\/strong> Klausner M, Anderson DJ<\/b>.\u00a0 Characterization of a Hormone-Responsive Organotypic Human Vaginal Tissue Model: Morphologic and Immunologic Effects.<\/a>\u00a0 Reprod Sci<\/span><\/em>. 2015 Feb 11. pii: 1933719115570906. [Epub ahead of print]<\/p>\n

7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chen A, McKinley SA, Shi F, Wang S, Mucha PJ, Harit D, Forest MG, Lai SK<\/b>. Modeling of Virion Collisions in Cervicovaginal Mucus Reveals Limits on Agglutination as the Protective Mechanism of Secretory Immunoglobulin A.<\/a> \u00a0PLoS One<\/span><\/em>. 2015 Jul 1;10(7):e0131351. doi: 10.1371\/journal.pone.0131351. eCollection 2015.<\/o:p><\/p>\n

8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nunn KL, Wang YY, Harit D, Humphrys MS, Ma B, Cone R<\/b>, Ravel J, Lai SK.<\/strong> Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated with Lactobacillus crispatus-Dominant Microbiota.<\/a> MBio<\/span><\/em>. 2015 Oct 6;6(5):e01084-15. doi: 10.1128\/mBio.01084-15.<\/o:p><\/p>\n

9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Santangelo PJ, Rogers KA, Zurla C, Blanchard EL, Gumber S, Strait K, Connor-Stroud F, Schuster DM, Amancha PK, Hong JJ, Byrareddy SN, Hoxie JA, Vidakovic B, Ansari AA, Hunter E, Villinger F<\/b>.\u00a0 Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques.<\/a>\u00a0 Nat Methods<\/span><\/em>. 2015 May;12(5):427-32. doi: 10.1038\/nmeth.3320. Epub 2015 Mar 9<\/p>\n

10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal DN, Villinger F<\/b>, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM.\u00a0 Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.\u00a0<\/a> Vaccine<\/span><\/em>. 2015 Apr 21;33(17):2086-95. doi: 10.1016\/j.vaccine.2015.02.020. Epub 2015 Mar 11.<\/p>\n

11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Abdel-Motal UM, Harbison C, Han T, Pudney J,<\/strong> Anderson DJ<\/b>, Zhu Q, Westmoreland S, Marasco WA.\u00a0 Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer.<\/a>\u00a0 Gene Ther<\/span><\/em>. 2014 Sep;21(9):802-10. doi: 10.1038\/gt.2014.56. Epub 2014 Jun 26.<\/p>\n

12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Anderson DJ<\/b>, Marathe J, Pudney J.<\/strong>\u00a0 The structure of the human vaginal stratum corneum and its role in immune defense.<\/a>\u00a0 Am J Reprod Immunol<\/span><\/em>. 2014 Jun;71(6):618-23. doi: 10.1111\/aji.12230. Epub 2014 Mar 24. Review.<\/p>\n

13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chen A, McKinley SA, Wang S, Shi F, Mucha PJ, Forest MG, Lai SK<\/b>.\u00a0 Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasion<\/a>.\u00a0 Biophys J<\/span><\/em>. 2014 May 6;106(9):2028-36. doi: 10.1016\/j.bpj.2014.02.038.<\/p>\n

14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 McKinley SA, Chen A, Shi F, Wang S, Mucha PJ, Forest MG, Lai SK<\/b>.\u00a0 Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.<\/a>\u00a0 PLoS One<\/span><\/em>. 2014 Jun 26;9(6):e100598. doi: 10.1371\/journal.pone.0100598. eCollection 2014.<\/p>\n

15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J,<\/strong> Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K<\/b>, Xu B, Strong JE, Zeitlin L,<\/strong> Kobinger GP.\u00a0 Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.<\/a>\u00a0 Nature<\/span><\/em>. 2014 Oct 2;514(7520):47-53. doi: 10.1038\/nature13777. Epub 2014 Aug 29.<\/p>\n

16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Wang YY, Kannan A, Nunn KL, Murphy MA, Subramani DB, Moench T<\/b>, Cone R<\/b>, Lai SK.<\/strong>\u00a0 IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections.<\/a>\u00a0 Mucosal Immunol<\/span>.<\/em> 2014 Sep;7(5):1036-44. doi: 10.1038\/mi.2013.120. Epub 2014 Feb 5.<\/p>\n

17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Whaley KJ, Morton J,<\/strong> Hume S, Hiatt E, Bratcher B,<\/strong> Klimyuk V, Hiatt A, Pauly M, Zeitlin L.\u00a0<\/strong> Emerging antibody-based products<\/a>.\u00a0 <\/a>Curr Top Microbiol Immunol<\/span>.<\/em> 2014;375:107-26. doi: 10.1007\/82_2012_240. Review.<\/p>\n

18.\u00a0\u00a0\u00a0\u00a0\u00a0 Cone RA.<\/strong> Vaginal microbiota and sexually transmitted infections that may influence transmission of cell-associated HIV.<\/a> \u00a0J Infect Dis.<\/em> 2014 Dec 15;210 Suppl 3:S616-21. doi: 10.1093\/infdis\/jiu459.<\/p>\n

19.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Aldunate M, Tyssen D, Johnson A, Zakir T, Sonza S, Moench T<\/b>, Cone R<\/b>, Tachedjian G.\u00a0 Vaginal concentrations of lactic acid potently inactivate HIV.<\/a>\u00a0 J Antimicrob Chemother<\/span>.<\/em> 2013 Sep;68(9):2015-25. doi: 10.1093\/jac\/dkt156. Epub 2013 May 8.<\/p>\n

20.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J<\/b>, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ,<\/strong> Forthal DN.\u00a0 The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.<\/a>\u00a0 PLoS Pathog<\/span><\/em>. 2013;9(11):e1003776. doi: 10.1371\/journal.ppat.1003776. Epub 2013 Nov 21.<\/p>\n

21.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B.\u00a0 Developing multipurpose reproductive health technologies: an integrated strategy<\/a>.\u00a0 AIDS Res Treat<\/span><\/em>. 2013;2013:790154. doi: 10.1155\/2013\/790154. Epub 2013 Feb 28.<\/p>\n

22.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hiatt A, Zeitlin L, Whaley KJ.\u00a0<\/strong> Multiantibody strategies for HIV.<\/a>\u00a0 Clin Dev Immunol<\/span><\/em>. 2013;2013:632893. doi: 10.1155\/2013\/632893. Epub 2013 Jun 6. Review.<\/p>\n

23.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 O’Hanlon DE, Moench TR,<\/strong> Cone RA<\/b>.\u00a0 Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota<\/a>.\u00a0 PLoS One<\/span><\/em>. 2013 Nov 6;8(11):e80074. doi: 10.1371\/journal.pone.0080074. eCollection 2013.<\/p>\n

24.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Whaley KJ, Zeitlin L.\u00a0<\/strong> Antibody-based concepts for multipurpose prevention technologies<\/a>.\u00a0 Antiviral Res<\/span><\/em>. 2013 Dec;100 Suppl:S48-53. doi: 10.1016\/j.antiviral.2013.09.027. Epub 2013 Nov 1. Review.<\/p>\n

25.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Abdel-Motal UM, Sarkis PT, Han T, Pudney J, Anderson DJ<\/strong>, Zhu Q, Marasco WA. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro<\/strong><\/a>.\u00a0 <\/a>PLoS One <\/em>2011,6:e26473.<\/p>\n

26.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Blaskewicz CD, Pudney J, Anderson DJ.\u00a0<\/strong> Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia.<\/a>\u00a0 Biol Reprod<\/span><\/em>. 2011 Jul;85(1):97-104. doi: 10.1095\/biolreprod.110.090423. Epub 2011 Apr 6.<\/p>\n

27.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Anderson DJ, Politch JA,<\/strong> Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH.\u00a0<\/strong> Targeting Trojan Horse leukocytes for HIV prevention.<\/a>\u00a0 AIDS<\/span>.<\/em> 2010 Jan 16;24(2):163-87. doi: 10.1097\/QAD.0b013e32833424c8. Review.<\/p>\n

28.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Anderson DJ, Pudney J,<\/strong> Schust DJ.\u00a0 Caveats associated with the use of human cervical tissue for HIV and microbicide research.<\/a>\u00a0 AIDS<\/span>.<\/em> 2010 Jan 2;24(1):1-4. doi: 10.1097\/QAD.0b013e328333acfb.<\/p>\n

29.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ayehunie S, Cannon C, Larosa K, Pudney J, Anderson DJ,<\/strong> Klausner M.\u00a0 Development of an in vitro alternative assay method for vaginal irritation.<\/a> Toxicology<\/span>. <\/em>2011 Jan 11;279(1-3):130-8. doi: 10.1016\/j.tox.2010.10.001. Epub 2010 Oct 17.<\/p>\n

30.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Whaley KJ,<\/strong> Hanes J, Shattock R, Cone RA<\/b>, Friend DR.\u00a0 Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.<\/a>\u00a0 Antiviral Res<\/span>.<\/em> 2010 Dec;88 Suppl 1:S55-66. doi: 10.1016\/j.antiviral.2010.09.006.<\/p>\n

Other Relevant Publications:\u00a0 <\/strong><\/p>\n

1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Abdel-Motal UM, Sarkis PT, Han T, Pudney J, Anderson DJ, Zhu Q, Marasco WA. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro<\/strong><\/a>. PLoS One <\/em>2011,6:e26473.<\/p>\n

2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, Trkola A.\u00a0 Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies<\/span><\/strong><\/a>.<\/span><\/strong>\u00a0 <\/a>PLoS Pathogens<\/em> 2012,4:e1002634.<\/p>\n

3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis<\/strong>.<\/a> Nature <\/em>2011,481:81-84.<\/p>\n

4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al.<\/em> Efficacy results of a trial of a herpes simplex vaccine<\/strong>.<\/a> N Engl J Med <\/em>2012,366:34-43.<\/p>\n

5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, et al.<\/em> Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody<\/strong>.<\/a> Proc Natl Acad Sci U S A <\/em>2011,108:11181-11186.<\/p>\n

6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chen W, Dimitrov DS. Monoclonal Antibody-Based Candidate Therapeutics Against HIV Type 1<\/strong>.<\/a> AIDS Res Hum Retroviruses <\/em>2011.<\/p>\n

7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Diskin R, Scheid JF, Marcovecchio PM, West AP, Jr., Klein F, Gao H, et al.<\/em> Increasing the potency and breadth of an HIV antibody by using structure-based rational design<\/strong>. <\/a>Science<\/em>,334:1289-1293.<\/p>\n

8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, et al.<\/em>Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine<\/strong>.<\/a> J Infect Dis <\/em>2010,202:595-605.<\/p>\n

9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Haigwood NL, Hirsch VM. Blocking and tackling HIV<\/strong>.<\/a> Nat Med <\/em>2009,15:841-842.<\/p>\n

10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al.<\/em> Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques<\/strong>.<\/a> Nat Med <\/em>2009,15:951-954.<\/p>\n

11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, et al.<\/em> Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L<\/strong>.<\/a> J Virol <\/em>2010,84:1302-1313.<\/p>\n

12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al.<\/em>\u00a0 Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.<\/a><\/strong> \u00a0Nature<\/em> 2012,491:406-12.<\/p>\n

13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al.\u00a0<\/em> HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.<\/a><\/strong>\u00a0 Nature<\/em> 2012, in press.<\/p>\n

14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection<\/strong>.<\/a> Proc Natl Acad Sci U S A <\/em>2011,108:4388-4393.<\/p>\n

15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Malbec M, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A, Scheid JF, Eden C, Mouquet H, Nussenzweig MC, Schwartz O.\u00a0 Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.<\/a><\/strong>\u00a0 J Exp Med<\/i> 2013 [Epub ahead of print]<\/p>\n

16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 McGhee JR. A mucosal gateway for vaccines<\/strong>.<\/a> Nat Biotechnol <\/em>2011,29:136-138.<\/p>\n

17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NIH News.\u00a0 NIH-led scientists find antibodies that prevent most HIV strains from infecting human cells.<\/a>\u00a0<\/strong> Bethesda:\u00a0 NIAID, NIH:\u00a0 2010.<\/p>\n

18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Owen DH, Katz DF.\u00a0 A vaginal fluid simulant.<\/a>\u00a0<\/strong> Contraception <\/em>\u00a01999,59:91-5.<\/p>\n

19.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PATH and the Coalition Advancing Multipurpose Innovations.\u00a0 Saving Lives with Multipurpose Prevention Technologies:\u00a0 Turning Ideas into Solutions for Sexual and Reproductive Health<\/strong>.<\/a> Seattle: 2010.<\/p>\n

20.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, et al.<\/em> A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield<\/strong>.<\/a> Science <\/em>2011,334:1097-1103.<\/p>\n

21.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, et al.<\/em>\u00a0 Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.<\/a>\u00a0<\/strong> Proc Natl Acad Sci USA <\/em>2010,107:11483-8.<\/p>\n

22.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine<\/a>?<\/strong> Nat Med <\/em>2009,15:866-870.<\/p>\n

23.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Veselinovic M, Neff CP, Mulder LR, Akkina R.\u00a0 Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model<\/span><\/strong><\/a>.<\/span><\/strong>\u00a0 Virology<\/em> 2012,432:505-510.<\/p>\n

24. \u00a0\u00a0\u00a0\u00a0\u00a0 Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, Safrit JT, Graham BS, Snow W.\u00a0 HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission.<\/a>\u00a0 PLoS Med<\/span>. 2014 Apr 8;11(4):e1001616. doi: 10.1371\/journal.pmed.1001616. eCollection 2014 Apr.<\/p>\n

25.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al.<\/em> Broad neutralization coverage of HIV by multiple highly potent antibodies<\/strong>.<\/a> Nature <\/em>2011,477:466-470.<\/p>\n

26.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al.<\/em> Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target<\/strong>.<\/a> Science <\/em>2009,326:285-289.<\/p>\n

27.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0West AP, Galimidi RP, Gnanapragasam PNP, Bjorkman PJ.\u00a0 Single-chain Fv-based anti-HIV proteins:\u00a0 potential and limitations.<\/a>\u00a0<\/span><\/strong> J Virol<\/em>\u00a0 2012,86:195-202.<\/p>\n

28.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Whaley KJ, Morton J, Hume S, Hiatt E, Bratcher B, Klimyuk V, Hiatt A, Pauly M, Zeitlin L.\u00a0 Emerging antibody-based products.<\/a>\u00a0<\/strong> Curr Top Microbiol Immunol<\/em> 2012,Jul 8. [Epub ahead of print]<\/p>\n

29.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Wu X, Wang C, O’Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR.\u00a0 Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.<\/a><\/span><\/strong>\u00a0 J Virol<\/em> 2012,86:5844-56.<\/p>\n

30.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. <\/em>Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1<\/strong>. <\/a>Science <\/em>2010,329:856-861.<\/p>\n

31.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X. Efficient mucosal vaccination mediated by the neonatal Fc receptor<\/strong>.<\/a> Nat Biotechnol <\/em>2011,29:158-163.<\/p>\n

32.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zhang MY, Borges AR, Ptak RG, Wang Y, Dimitrov AS, Alam SM, et al.<\/em> Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1<\/strong>.<\/a> MAbs <\/em>2010,2:266-274.<\/p>\n

33.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al.<\/em> Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01<\/strong>.<\/a> Science <\/em>2010,329:811-817.<\/p>\n","protected":false},"excerpt":{"rendered":"

Publication of Clinical Trial Results Politch JA, Cu-Uvin S, Moench TR, Tashima KT, Marathe JG, Guthrie KM, Cabral H, Nyhuis T, Brennan M, Zeitlin L, Spiegel HML, Mayer KH, Whaley KJ, Anderson DJ. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): \u00a0A Phase I randomized trial. PLoS Med, 2021;18(2):e1003495. __________________________________________________ […]<\/p>\n","protected":false},"author":5393,"featured_media":0,"parent":0,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/ipcp\/wp-json\/wp\/v2\/pages\/59"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/ipcp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/ipcp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/ipcp\/wp-json\/wp\/v2\/users\/5393"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/ipcp\/wp-json\/wp\/v2\/comments?post=59"}],"version-history":[{"count":50,"href":"https:\/\/www.bumc.bu.edu\/ipcp\/wp-json\/wp\/v2\/pages\/59\/revisions"}],"predecessor-version":[{"id":725,"href":"https:\/\/www.bumc.bu.edu\/ipcp\/wp-json\/wp\/v2\/pages\/59\/revisions\/725"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/ipcp\/wp-json\/wp\/v2\/media?parent=59"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}